Penetration of paclitaxel and 5-fluorouracil in multicellular layers of human colorectal cancer cells

Oncology Reports

Volumn 25, Issue 3, 2011, Pages 863-870

  Choi, Mi Sun ^a   Kim, Soo Hyun ^a   Kuh, Hyo Jeong ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

5 fluorouracil; Drug combination; Drug penetration; Multicellular layer; Paclitaxel

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PACLITAXEL;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN DLD 1; CELL STRAIN HT 29; CELL SURVIVAL; COLORECTAL CANCER; CYTOTOXICITY; DRUG PENETRATION; HUMAN; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL AVAILABILITY; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FLUOROURACIL; HT29 CELLS; HUMANS; MODELS, BIOLOGICAL; PACLITAXEL; TRANSCYTOSIS;

EID: 79551605530     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1138     Document Type: Article

References (28)

1. Desoize B and Jardillier J: Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol 36: 193-207, 2000.
2. Minchinton AI and Tannock IF: Drug penetration in solid tumours. Nat Rev Cancer 6: 583-589, 2006.
3. Trédan O, Galmarini CM, Patel K and Tannock IF: Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99: 1441-1454, 2007.
4. Cowan DS, Hicks KO and Wilson WR: Multicellular membranes as an in vitro model for extravascular diffusion in tumours. Br J Cancer 27: S28-S31, 1996.
5. Tannock IF, Lee CM, Tunggal JK, Cowan DS and Egorin MJ: Limited penetration of anticancer drugs through tumor tissue. Clin Cancer Res 8: 878-884, 2002.
6. Primeau AJ, Rendon A, Hedley D, Lilge L and Tannock IF: The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 11: 8782-8788, 2005. (Pubitemid 43005929)
7. Kuh HJ, Jang SH, Wientjes MG, Weaver JR and Au JL: Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther 290: 871-880, 1999.
8. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, Hanahan D, Mattrey RF and Ruoslahti E: Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16: 510-520, 2009.
9. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR and Ruoslahti E: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328: 1031-1035, 2010.
10. Hicks KO, Ohms SJ, van Zijl PL, Denny WA, Hunter PJ and Wilson WR: An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours. Br J Cancer 76: 894-903, 1997.
11. Wilson WR and Hicks KO: Measurement of extravascular drug diffusion in multicellular layers. Br J Cancer 79: 1623-1626, 1999.
12. Phillips RM, Loadman PM and Cronin BP: Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. Br J Cancer 77: 2112-2119, 1998.
13. Tunggal JK, Cowan DS, Shaikh H and Tannock IF: Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. Clin Cancer Res 5: 1583-1586, 1999.
14. Tunggal JK, Melo T, Ballinger JR and Tannock IF: The influence of expression of P-glycoprotein on the penetration of anticancer drugs through multicellular layers. Int J Cancer 86: 101-107, 2000.
15. Cowan DS and Tannock IF: Factors that influence the penetration of methotrexate through solid tissue. Int J Cancer 91: 120-125, 2001.
16. Grantab R, Sivananthan S and Tannock IF: The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res 66: 1033-1039, 2006.
17. Kang GH, Kim GS, Lee HR, Yuh YJ and Kim SR: A phase II trial of paclitaxel, 5-fluorouracil (5-FU) and cisplatin in patients with metastatic or recurrent gastric cancer. Cancer Res Treat 40: 106-110, 2008.
18. Lu D, Wientjes MG, Lu Z and Au JL: Tumor priming enhances delivery and efficacy of nanomedicines. J Pharmacol Exp Ther 322: 80-88, 2007. (Pubitemid 46956353)
19. Baker JH, Lam J, Kyle AH, Sy J, Oliver T, Co SJ, Dragowska WH, Ramsay E, Anantha M, Ruth TJ, Adam MJ, Yung A, Kozlowski P, Minchinton AI, Ng SS, Bally MB and Yapp DT: Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin. Clin Cancer Res 14: 7260-7271, 2008.
20. Erlichman C and Wu A: Effects of 5-fluorouracil and leucovorin in spheroids: a model for solid tumours. Anticancer Res 11: 671-675, 1991.
21. Lowthers EL, Richard CL and Blay J: Differential sensitivity to short-chain ceramide analogues of human intestinal carcinoma cells grown in tumor spheroids versus monolayer culture. In Vitro Cell Dev Biol Anim 39: 340-342, 2003.
22. Nederman T and Carlsson J: Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids. Cancer Chemother Pharmacol 13: 131-135, 1984. (Pubitemid 14091967)
23. Dombernowsky P, Gehl J, Boesgaard M, Paaske T and Jensen BV: Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer. Semin Oncol 23: 23-27, 1996. (Pubitemid 26362181)
24. Miyazaki K, Shibahara T, Sato D, Uchida K, Suzuki H, Matsui H, Yanaka A, Nakahara A and Matsuzaki Y: Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. J Gastroenterol 41: 140-150, 2006.
25. Oh J-M, Ryu Y-K, Lim J-S and Moon E-Y: Hypoxia induces paclitaxel-resistance through ROS production. Biomol Ther 18: 145-151, 2010.
26. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
27. St Croix B, Man S and Kerbel RS: Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors. Cancer Lett 131: 35-44, 1998.
28. Lee CM and Tannock IF: Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration. Br J Cancer 94: 863-869, 2006.